ArticleJournal of ovarian research2026
Revisiting ESR in PCOS: an easily obtainable link to immune and metabolic dysregulation.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPolycystic ovary syndrome (PCOS) is closely associated with systemic low-grade inflammation, yet evidence regarding erythrocyte sedimentation rate (ESR), a cost-effective and stable inflammatory marker, in reproductive-aged women without comorbidities remains limited, particularly its relationships with metabolic-endocrine parameters. This study aimed to characterize ESR dynamics in reproductive-aged women with PCOS who have no systemic comorbidities versus normo-ovulatory controls, and to evaluate its associations with endocrine and metabolic disturbances while controlling for systemic confounders.
methodsIn this retrospective analysis, we enrolled a total of 2,006 women diagnosed with PCOS and 10,038 normo-ovulatory women as controls. ESR was measured using an automated ESR analyzer, and metabolic-endocrine parameters (lipid profile, hepatic/renal function, and reproductive hormones) were quantified using automated immunoassays. The alterations in ESR levels and their associations with endocrine and metabolic conditions were assessed.
resultsPCOS women exhibited significantly elevated ESR levels across all age/BMI strata, with a higher hyper-ESR (ESR > 20 mm/h) prevalence. ESR was positively correlated with atherogenic lipids and renal/hepatic function. LH/FSH ratio, TT, and atherogenic lipids contributd to hyper-ESR in both PCOS and control groups, indicating neuroendocrine/metabolism-inflammation crosstalk. Despite associations, ESR demonstrated low discriminative performance for incident PCOS and suboptimal predictive value for dyslipidemia/hyperandrogenemia across distinct populations.
conclusionsThis large-scale study suggests ESR may serve as an accessible biomarker of chronic inflammation associated with PCOS, which is linked to metabolic-endocrine dysregulation. The findings offer new insights into the pathophysiology of PCOS and may support the clinical utility of ESR in monitoring disease severity and guiding anti-inflammatory interventions in PCOS women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.